Agilon Health, Inc. (NYSE:AGL - Get Free Report) has been assigned an average recommendation of "Hold" from the eighteen analysts that are covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating and four have issued a buy rating on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $3.0714.
AGL has been the topic of several recent analyst reports. Benchmark cut their price objective on Agilon Health from $4.00 to $1.50 and set a "buy" rating on the stock in a report on Wednesday, August 6th. The Goldman Sachs Group lifted their target price on Agilon Health from $2.50 to $5.00 and gave the company a "neutral" rating in a research note on Thursday, May 8th. Barclays lowered their target price on Agilon Health from $3.00 to $1.50 and set an "underweight" rating on the stock in a research note on Wednesday, August 6th. Wells Fargo & Company lowered their target price on Agilon Health from $6.00 to $5.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 13th. Finally, Sanford C. Bernstein reaffirmed a "market perform" rating and set a $1.40 target price (down previously from $4.00) on shares of Agilon Health in a research note on Wednesday, August 20th.
Check Out Our Latest Report on Agilon Health
Agilon Health Stock Up 3.8%
Agilon Health stock traded up $0.05 during midday trading on Monday, hitting $1.25. The company's stock had a trading volume of 3,301,241 shares, compared to its average volume of 7,131,675. The stock's 50-day moving average price is $1.72 and its 200-day moving average price is $2.87. The company has a market capitalization of $515.96 million, a PE ratio of -1.62 and a beta of 0.11. Agilon Health has a 12 month low of $0.71 and a 12 month high of $6.08.
Agilon Health (NYSE:AGL - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.14). The company had revenue of $1.39 billion for the quarter, compared to analyst estimates of $1.47 billion. Agilon Health had a negative return on equity of 66.76% and a negative net margin of 5.35%.Agilon Health's quarterly revenue was down 5.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.07) EPS. As a group, equities analysts anticipate that Agilon Health will post -0.59 EPS for the current year.
Hedge Funds Weigh In On Agilon Health
Institutional investors and hedge funds have recently bought and sold shares of the business. Nisa Investment Advisors LLC grew its stake in Agilon Health by 244.9% during the 1st quarter. Nisa Investment Advisors LLC now owns 9,553 shares of the company's stock valued at $41,000 after acquiring an additional 6,783 shares in the last quarter. Gabelli Funds LLC bought a new stake in shares of Agilon Health in the 1st quarter valued at approximately $48,000. Arrowpoint Investment Partners Singapore Pte. Ltd. bought a new stake in shares of Agilon Health in the 2nd quarter valued at approximately $31,000. Ridgecrest Wealth Partners LLC bought a new stake in shares of Agilon Health in the 1st quarter valued at approximately $65,000. Finally, Pallas Capital Advisors LLC bought a new stake in shares of Agilon Health in the 1st quarter valued at approximately $66,000.
Agilon Health Company Profile
(
Get Free Report)
agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc and changed its name to agilon health, inc.
Featured Stories

Before you consider Agilon Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agilon Health wasn't on the list.
While Agilon Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.